FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912155276> ?p ?o ?g. }

• W2912155276 endingPage "264" @default.
• W2912155276 startingPage "253" @default.
• W2912155276 abstract "Background Doubts exist regarding optimal second-line treatment options for HIV-1-infected patients in resource-limited settings. We assessed safety and efficacy of dolutegravir compared with ritonavir-boosted lopinavir, plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults in whom previous first-line antiretroviral therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two NRTIs has failed. Methods DAWNING is a phase 3b, open-label, parallel-group, non-inferiority, active-controlled trial done at 58 sites in 13 countries. Eligible adults were aged at least 18 years and, during at least 6 months of treatment with a first-line treatment containing an NNRTI and two NRTIs, had virological failure (confirmed HIV-1 RNA ≥400 copies per mL). Participants were randomly assigned by a central randomisation system to receive oral dolutegravir (50 mg once daily) or ritonavir-boosted lopinavir (800 mg lopinavir plus 200 mg ritonavir once daily or 400 mg plus 100 mg twice daily), plus two investigator-selected NRTIs (at least one fully active based on resistance testing at screening). The primary outcome was the proportion of participants achieving viral suppression (defined as plasma HIV-1 RNA <50 copies per mL) at week 48 using the snapshot algorithm and a non-inferiority margin of −12%. The primary analysis was done in an intention-to-treat-exposed (ITT-E) population of participants who received at least one dose of study medication, according to original group assignment. Safety was analysed in all participants who received at least one dose of study drug, according to which drug was received. The study was registered at ClinicalTrials.gov, number NCT02227238, and viiv-studyregister.com, number 200304. Findings Between Dec 11, 2014, and June 27, 2016, 968 adults were screened and 627 were randomly assigned to the dolutegravir group (n=312) or the ritonavir-boosted lopinavir group (n=315). Three patients in the ritonavir-boosted lopinavir group did not receive study medication and so 624 were included in the ITT-E population. At week 48, 261 (84%) of 312 participants in the dolutegravir group achieved viral suppression compared with 219 (70%) of 312 in the ritonavir-boosted lopinavir group (adjusted difference 13·8%; 95% CI 7·3–20·3). Non-inferiority was achieved on the basis of the 95% CI of the adjusted treatment difference having a lower bound greater than −12% (prespecified non-inferiority margin). Because the lower bound of the 95% CI is greater than zero (7·3%), superiority of dolutegravir was also concluded (p<0·0001). The safety profile for dolutegravir was favourable compared with that of ritonavir-boosted lopinavir. More grade 2–4 drug-related adverse events occurred with ritonavir-boosted lopinavir than dolutegravir (44 [14%] of 310 with ritonavir-boosted lopinavir vs 11 [4%] of 314 with dolutegravir), mainly driven by gastrointestinal disorders. Interpretation When administered with two NRTIs, dolutegravir was superior to ritonavir-boosted lopinavir at 48 weeks and can be considered a suitable option for second-line treatment. Funding ViiV Healthcare." @default.
• W2912155276 created "2019-02-21" @default.
• W2912155276 creator A5008962181 @default.
• W2912155276 creator A5017960080 @default.
• W2912155276 creator A5021048736 @default.
• W2912155276 creator A5023532475 @default.
• W2912155276 creator A5030471784 @default.
• W2912155276 creator A5031626579 @default.
• W2912155276 creator A5042629578 @default.
• W2912155276 creator A5042699030 @default.
• W2912155276 creator A5056086220 @default.
• W2912155276 creator A5056846000 @default.
• W2912155276 creator A5057393643 @default.
• W2912155276 creator A5059809637 @default.
• W2912155276 creator A5061678587 @default.
• W2912155276 creator A5061795556 @default.
• W2912155276 creator A5072290553 @default.
• W2912155276 creator A5079967288 @default.
• W2912155276 creator A5083504573 @default.
• W2912155276 date "2019-03-01" @default.
• W2912155276 modified "2023-10-10" @default.
• W2912155276 title "Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial" @default.
• W2912155276 cites W1761275020 @default.
• W2912155276 cites W1767400858 @default.
• W2912155276 cites W2025740330 @default.
• W2912155276 cites W2062514953 @default.
• W2912155276 cites W2068866500 @default.
• W2912155276 cites W2094241860 @default.
• W2912155276 cites W2094811879 @default.
• W2912155276 cites W2125756020 @default.
• W2912155276 cites W2130068726 @default.
• W2912155276 cites W2139430929 @default.
• W2912155276 cites W2149717057 @default.
• W2912155276 cites W2285921033 @default.
• W2912155276 cites W2338494325 @default.
• W2912155276 cites W2562322368 @default.
• W2912155276 cites W2612187578 @default.
• W2912155276 cites W2735576184 @default.
• W2912155276 cites W2742200330 @default.
• W2912155276 cites W2794150437 @default.
• W2912155276 cites W2883284210 @default.
• W2912155276 doi "https://doi.org/10.1016/s1473-3099(19)30036-2" @default.
• W2912155276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30732940" @default.
• W2912155276 hasPublicationYear "2019" @default.
• W2912155276 type Work @default.
• W2912155276 sameAs 2912155276 @default.
• W2912155276 citedByCount "105" @default.
• W2912155276 countsByYear W29121552762019 @default.
• W2912155276 countsByYear W29121552762020 @default.
• W2912155276 countsByYear W29121552762021 @default.
• W2912155276 countsByYear W29121552762022 @default.
• W2912155276 countsByYear W29121552762023 @default.
• W2912155276 crossrefType "journal-article" @default.
• W2912155276 hasAuthorship W2912155276A5008962181 @default.
• W2912155276 hasAuthorship W2912155276A5017960080 @default.
• W2912155276 hasAuthorship W2912155276A5021048736 @default.
• W2912155276 hasAuthorship W2912155276A5023532475 @default.
• W2912155276 hasAuthorship W2912155276A5030471784 @default.
• W2912155276 hasAuthorship W2912155276A5031626579 @default.
• W2912155276 hasAuthorship W2912155276A5042629578 @default.
• W2912155276 hasAuthorship W2912155276A5042699030 @default.
• W2912155276 hasAuthorship W2912155276A5056086220 @default.
• W2912155276 hasAuthorship W2912155276A5056846000 @default.
• W2912155276 hasAuthorship W2912155276A5057393643 @default.
• W2912155276 hasAuthorship W2912155276A5059809637 @default.
• W2912155276 hasAuthorship W2912155276A5061678587 @default.
• W2912155276 hasAuthorship W2912155276A5061795556 @default.
• W2912155276 hasAuthorship W2912155276A5072290553 @default.
• W2912155276 hasAuthorship W2912155276A5079967288 @default.
• W2912155276 hasAuthorship W2912155276A5083504573 @default.
• W2912155276 hasConcept C126322002 @default.
• W2912155276 hasConcept C142462285 @default.
• W2912155276 hasConcept C159047783 @default.
• W2912155276 hasConcept C2777182164 @default.
• W2912155276 hasConcept C2777351918 @default.
• W2912155276 hasConcept C2779298103 @default.
• W2912155276 hasConcept C2779465607 @default.
• W2912155276 hasConcept C2779502633 @default.
• W2912155276 hasConcept C2781392899 @default.
• W2912155276 hasConcept C2908647359 @default.
• W2912155276 hasConcept C2909970146 @default.
• W2912155276 hasConcept C2993143319 @default.
• W2912155276 hasConcept C3013748606 @default.
• W2912155276 hasConcept C71924100 @default.
• W2912155276 hasConcept C99454951 @default.
• W2912155276 hasConceptScore W2912155276C126322002 @default.
• W2912155276 hasConceptScore W2912155276C142462285 @default.
• W2912155276 hasConceptScore W2912155276C159047783 @default.
• W2912155276 hasConceptScore W2912155276C2777182164 @default.
• W2912155276 hasConceptScore W2912155276C2777351918 @default.
• W2912155276 hasConceptScore W2912155276C2779298103 @default.
• W2912155276 hasConceptScore W2912155276C2779465607 @default.
• W2912155276 hasConceptScore W2912155276C2779502633 @default.
• W2912155276 hasConceptScore W2912155276C2781392899 @default.
• W2912155276 hasConceptScore W2912155276C2908647359 @default.
• W2912155276 hasConceptScore W2912155276C2909970146 @default.
• W2912155276 hasConceptScore W2912155276C2993143319 @default.
• W2912155276 hasConceptScore W2912155276C3013748606 @default.

• next